Abstract 1829P
Background
To investigate the nutritional status of hospitalized patients with common malignant tumor in a cancer hospital of Southwest China.
Methods
From April 2017 to May 2021, we enrolled 891 patients with cancer hospitalized for treatment in Chongqing university Cancer Hospital. These patients were diagnosed with one of the following 16 different types of malignant tumors: lung cancer, gastric cancer, liver cancer, colorectal cancer, breast cancer, esophageal cancer, cervical cancer, endometrial cancer, nasopharyngeal carcinoma, malignant lymphoma, leukemia, pancreatic cancer, ovarian cancer, prostate cancer, bladder cancer and brain tumor. Patient-generated subjective global assessment (PG-SGA), anthropometric measurements, and laboratory examination were used to evaluate the nutritional risk or nutritional status.Cancer pain status were assessed with the Numerical Rating Scale (NRS). We also investigated the nutritional therapy of these cancer patients.
Results
According to the PG-SGA score, 48.7% (434/891) of the cancer patients were severe malnutrition (PG-SGA≥9), 31.2% (312/891) were moderate malnutrition (8≥PG-SGA≥4), 14.7% (131/891) were mild malnutrition (PG-SGA 2∼3), and only 5.4% (48/891) patients were no malnutrition (PG-SGA 0∼1). The rate of malnutrition for gastrointestinal cancer patients is higher than Nongastrointestinal cancer patients (67.3% vs. 44.6%, χ2=31.48, P <0.001). Multiple linear regression analysis, PG-SGA scores and body mass index (P<0.001), serum total protein(P<0.001), hemoglobin serum(P<0.001), albumin (P<0.001), prealbumin (P<0.001), calf circumference (left side, P=0.001) were correlated. Age(≥65 years), albumin(<40g/L), prealbumin (<150mg/L) and cancer pain (NRS≥4) are the risk factors of severe malnutrition. However, only 26.8% (200/746) of all the moderately and severely malnourished patients received nutritional therapy.
Conclusions
94.6% of the common malignant tumor patients enrolled in the present study were malnutrition. Nutritional therapy of malignant tumor patients with malnutrition is very low.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1843P - Safety of immunotherapy in cancer patients with comorbidities: Results of the phase IV Italian immuno-special trial
Presenter: Davide Smussi
Session: Poster session 12
1844P - 3-year experience of the Belgian multidisciplinary immunotoxicity board (BITOX): A nationwide initiative of the Belgian Society of Medical Oncology (BSMO)
Presenter: Marthe Verhaert
Session: Poster session 12
1845P - The impact of body mass index (BMI) on immune-related adverse events (irAEs) and acute care use among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Presenter: Zac Coyne
Session: Poster session 12
1846P - Social determinants of health in studies assessing toxicities associated with immune checkpoint inhibitor treatment: A systematic review
Presenter: Sofia Georgopoulou
Session: Poster session 12
1847P - Safety and efficacy of immune checkpoint inhibitors in patients over 85 years: ICIPO85 study
Presenter: MYRTILLE THOMAS
Session: Poster session 12
1848P - Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: Multicentre experience
Presenter: Onur Bas
Session: Poster session 12
1849P - Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort
Presenter: Víctor Albarrán Fernández
Session: Poster session 12
1850P - Management and potential factors of immunotoxicity in patients with metastatic non-small cell lung cancer receiving first-line treatment with immune checkpoint inhibitors
Presenter: Jesús Peña-Lopez
Session: Poster session 12
1851P - Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysis
Presenter: Taha Koray Sahin
Session: Poster session 12
1852P - The use of patient-reported outcome measures to assess toxicities and quality of life associated with immune checkpoint inhibitor therapy: A systematic review
Presenter: Poorni Jaganathan
Session: Poster session 12